Ayala Pharmaceuticals (NASDAQ:ADXS) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report issued on Tuesday. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Performance

NASDAQ ADXS opened at $0.57 on Tuesday. Ayala Pharmaceuticals has a one year low of $0.50 and a one year high of $1.95. The company’s 50 day moving average price is $0.71 and its 200 day moving average price is $0.75. The firm has a market capitalization of $6.15 million, a price-to-earnings ratio of -0.07 and a beta of 1.62.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.